<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diabetic ketoacidosis in children: Cerebral injury (cerebral edema)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diabetic ketoacidosis in children: Cerebral injury (cerebral edema)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diabetic ketoacidosis in children: Cerebral injury (cerebral edema)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicole Glaser, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph I Wolfsdorf, MD, BCh</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrienne G Randolph, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 17, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cerebral injury (cerebral edema) is an uncommon but potentially devastating consequence of diabetic ketoacidosis (DKA). This complication is far more common among children with DKA than among adults. Children presenting with more severe DKA (higher blood urea nitrogen levels and more severe acidosis and hypocapnia) are at greatest risk [<a href="#rid1">1-4</a>]. These children are often younger and newly diagnosed with diabetes due to the greater difficulty detecting symptoms in these children, which leads to delayed diagnoses and more severe presentations. Symptoms of cerebral injury may be present prior to initiation of therapy or emerge during treatment. In most cases, symptoms become apparent within 12 hours after the initiation of therapy and, rarely, later than 24 hours [<a href="#rid2">2,5-7</a>].</p><p>The pathophysiology, diagnosis, and treatment of cerebral injury in children with DKA will be discussed here. The diagnosis and treatment of DKA in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/5809.html" rel="external">"Diabetic ketoacidosis in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5808.html" rel="external">"Diabetic ketoacidosis in children: Treatment and complications"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>Clinically significant cerebral injury occurs in 0.3 to 0.9 percent of episodes of DKA in children and has a mortality rate of 20 to 25 percent [<a href="#rid1">1-3,8,9</a>]. Overall mortality rates for DKA in children and adolescents range from 0.15 to 0.51 percent in national population studies in Canada, the United Kingdom, and the United States [<a href="#rid1">1,5,10-13</a>]; 50 to 80 percent of diabetes-related deaths in children are caused by cerebral injury [<a href="#rid2">2,14</a>].</p><p>Subclinical cerebral edema, as detected by ventricular narrowing on imaging studies or alterations in brain water distribution on magnetic resonance imaging (MRI), has been reported in the majority of children with DKA, even in the absence of neurologic signs or symptoms  (<a class="graphic graphic_diagnosticimage graphicRef118292" href="/d/graphic/118292.html" rel="external">image 1</a>) [<a href="#rid6">6,15,16</a>]. In a study of 41 children with DKA, the width of the lateral ventricles (measured by MRI) was significantly smaller in patients during treatment for DKA than after recovery (mean width 9.3±0.3 versus 10.2±0.3 mm, respectively) [<a href="#rid16">16</a>]. Fifty-six percent of the children had ventricular narrowing during treatment. In this study, ventricular narrowing was more common in children who had subtle mental status abnormalities during DKA (abnormal Glasgow Coma Scale scores). In addition, subclinical cerebral edema detected by diffusion-weighted MRI is more severe in children who present with risk factors for clinically apparent cerebral injury (greater hyperventilation, higher blood urea nitrogen levels) [<a href="#rid17">17</a>].</p><p>Multiple lines of evidence suggest that subtle cerebral injury occurs commonly during DKA, and it is possible that clinically apparent cerebral injury may represent the most severe presentation of an otherwise common phenomenon. (See <a class="local">'Outcome'</a> below.)</p><p class="headingAnchor" id="H9915119"><span class="h1">PATHOPHYSIOLOGY</span></p><p class="headingAnchor" id="H1380968028"><span class="h2">Initial theories based on osmotic change</span><span class="headingEndMark"> — </span>The cause of DKA-related cerebral injury is not fully understood. In the 1980s, retrospective studies documented an increased frequency of cerebral injury in children who received intravenous fluids at higher rates [<a href="#rid18">18,19</a>]. It was therefore proposed that cerebral injury results from osmotic changes and fluid shifts during DKA. According to this theory, the hyperosmolar state during DKA causes brain cells to accumulate intracellular osmolytes. During DKA treatment, a decline in intravascular osmolality results in osmotically mediated movement of water into brain cells, causing cerebral edema and increased intracranial pressure and resulting in cerebral injury [<a href="#rid18">18,20,21</a>]. This theory was widely adopted, leading many pediatric DKA guidelines to recommend conservative rehydration strategies with slow intravenous infusions of isotonic fluids.</p><p>Over time, however, multiple lines of evidence have challenged the theory that cerebral injury is caused primarily by osmotic changes and fluid shifts:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PECARN FLUID trial (2018)</strong> – The most definitive investigation of the relationship of intravenous fluid treatment to cerebral injury in children with DKA comes from the "PECARN FLUID" (Pediatric Emergency Care Applied Research Network, Fluid Therapies Under Investigation in DKA) trial [<a href="#rid22">22</a>]. This trial examined neurologic outcomes of DKA in 1389 children randomized to one of four intravenous fluid treatment regimens to compare rapid versus slow rehydration and use of 0.45 versus 0.9% sodium chloride (NaCl) fluids, using a 2 × 2 factorial design. There were no significant differences between arms in mental status during DKA treatment (percentage of patients with a significant decline in Glasgow Coma Scale scores or alterations in tests of working memory), nor in rates of clinically apparent cerebral injury. Contrary to previous hypotheses, analyses of the subgroup with more severe DKA (pH or partial pressure of carbon dioxide [pCO<sub>2</sub>] in the lowest quartiles of the study population) suggested that more rapid fluid infusion was associated with more rapid improvement in scores on working memory tests during DKA treatment. Tests of memory and intelligence quotient (IQ) two to six months after recovery from DKA showed no differences between the four fluid treatment arms. These data underscore the lack of causal association between intravenous fluid therapies and DKA-related cerebral injury, at least within the range used in this trial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional</strong> <strong>evidence</strong> <strong>against osmolar change as a cause of DKA-related cerebral injury</strong> – Early studies comparing children with DKA-related cerebral injury with those with uncomplicated DKA were limited because they were not adjusted for factors related to DKA severity. By contrast, subsequent larger studies adjusting for DKA severity (including degree of acidosis and dehydration) did not find associations between fluid infusion rates and cerebral injury [<a href="#rid2">2</a>]. In addition, properly controlled studies of risk factors for DKA-related cerebral injury have not found associations between higher initial glucose levels or higher osmolality and risk for cerebral injury [<a href="#rid2">2,3</a>]. Similarly, declines in glucose and osmolality during treatment have not been associated with risk of cerebral injury [<a href="#rid2">2</a>]. Although retrospective studies found associations between declines in serum sodium levels during DKA treatment and risk of cerebral injury, a prospective study found no such association [<a href="#rid23">23</a>]. In this study, the frequencies of mental status changes and clinical diagnoses of cerebral injury were no different in children who had declines in sodium levels during treatment versus those who did not. These data suggest that associations between serum sodium decline and cerebral injury in previous retrospective studies may have reflected delayed diagnoses of cerebral injury, leading to complications involving abnormal sodium and fluid regulation (eg, syndrome of inappropriate secretion of antidiuretic hormone [SIADH] or cerebral salt-wasting syndrome). Finally, case reports and case series document the occurrence of severe and even fatal cerebral injury or cerebral edema occurring before treatment of DKA, including reports of deaths at home in children with diabetes found to have cerebral injury or cerebral edema at autopsy  (<a class="graphic graphic_diagnosticimage graphicRef118292" href="/d/graphic/118292.html" rel="external">image 1</a>) [<a href="#rid5">5,7,24</a>]. Studies demonstrate that at least 5 to 19 percent of clinically apparent DKA-related cerebral injuries occur before initiation of DKA treatment in the emergency department [<a href="#rid1">1,2</a>], suggesting that intravenous fluid therapy cannot be solely responsible for causing cerebral injury. A study found that children with DKA who have cerebral injury at the time of presentation to the emergency department have the same risk factors (high blood urea nitrogen concentrations and severe acidosis) as those who develop cerebral injury during DKA treatment [<a href="#rid25">25</a>]. These findings again suggest that factors intrinsic to DKA, rather than treatment-related factors, are responsible for cerebral injury.</p><p></p><p>Studies documenting imaging findings in children with severe DKA-related brain injuries also provide important information regarding causation. One large case series examined radiographic findings in children with profound neurologic alterations during DKA who were diagnosed with "cerebral edema" [<a href="#rid26">26</a>]. In this series, 39 percent had no evidence of edema on radiographic studies done at the time of neurologic decline but developed edema hours to days later. These findings suggest that edema may be a consequence of injury rather than the main cause, similar to edema that results from cellular energy failure during hypoxic-ischemic brain injuries. Studies using magnetic resonance imaging (MRI) to evaluate changes in brain water distribution during DKA also provide evidence to inform theories on causation. Diffusion-weighted MRI studies demonstrate that subclinical cerebral edema occurring during DKA in children is vasogenic, with increased accumulation of water in the extracellular space [<a href="#rid27">27-29</a>]. This finding is counter to what would be expected from edema caused by osmotic fluid shifts, where increased intracellular water content (cell swelling) would be anticipated, and suggests that abnormalities in blood-brain barrier function may occur during DKA [<a href="#rid30">30,31</a>].</p><p class="headingAnchor" id="H2416582988"><span class="h2">Current theories of cerebral hypoperfusion and neuroinflammation</span><span class="headingEndMark"> — </span>Several lines of evidence suggest that cerebral hypoperfusion may occur during DKA and that hypoperfusion/reperfusion may play a role in causing DKA-related cerebral injury.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluctuation in cerebral blood flow</strong> – In a rat model, studies using MR spectroscopy to measure cerebral metabolism during DKA demonstrate elevated levels of lactate in the brain, as well as decreased high-energy phosphate levels and low N-acetylaspartate:creatine ratio, a marker of neuronal integrity  (<a class="graphic graphic_figure graphicRef118212" href="/d/graphic/118212.html" rel="external">figure 1</a>) [<a href="#rid30">30</a>]. In humans who died from DKA-related cerebral injury, autopsy results also show findings similar to hypoxic-ischemic injury [<a href="#rid32">32-34</a>]. In addition, clinical studies demonstrate that factors affecting cerebral blood flow during DKA (dehydration and hypocapnia) are most strongly associated with risks of both life-threatening and more subtle cerebral injury in children [<a href="#rid2">2,17</a>]. In a rat DKA model, cerebral blood flow is reduced and gradually rises during treatment with insulin and intravenous fluids [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1">Although there are no data documenting cerebral blood flow during untreated DKA (ie, before treatment commences) in humans, several studies have assessed cerebral blood flow during DKA treatment. These studies show elevated cerebral blood flow, along with increased extracellular water content, consistent with hyperemia and associated vasogenic cerebral edema [<a href="#rid27">27-29</a>]. Studies using near-infrared spectroscopy during DKA treatment show elevated regional cerebral oxygen saturation, suggesting that cerebral blood flow is elevated in excess of metabolic demand [<a href="#rid28">28</a>]. This abnormal elevation in cerebral blood flow may persist for hours after DKA resolution. Studies using transcranial Doppler ultrasound also document abnormalities in cerebral autoregulation during DKA [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory responses</strong> – Although alterations in cerebral blood flow appear to play a role in DKA-related cerebral injury, the cerebral blood flow reduction caused by dehydration and hypocapnia alone is unlikely to be sufficient to cause substantial ischemic injury. Studies suggest that inflammatory factors present during DKA may act synergistically with hypoperfusion/reperfusion to cause injury or may increase the vulnerability of the brain to ischemic injury. DKA elicits a marked systemic inflammatory response, and several inflammatory factors may play a role in causing neuroinflammation or affecting the function of the blood-brain barrier [<a href="#rid38">38-41</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>As an example, children with DKA have altered matrix metalloproteinases (MMP) levels and these are correlated with levels of various inflammatory mediators (CXCL8, IL1-beta), some of which also increase leukocyte adhesion to blood-brain barrier endothelia [<a href="#rid42">42,43</a>]. MMPs are endopeptidases that degrade tight junction proteins and endothelial basement membranes, allowing fluid and blood-borne proinflammatory/neurotoxic proteins to invade the central nervous system. MMPs have been implicated as mediators of blood-brain barrier dysfunction in many disease states characterized by systemic inflammation with associated cerebral injury. The observed patterns of change in MMPs during DKA are similar to those documented during cerebral ischemia/reperfusion in studies of stroke [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Furthermore, studies using immunohistochemistry in a rat DKA model demonstrate a neuroinflammatory response involving reactive astrogliosis in the hippocampus and activation of microglia in most brain regions  (<a class="graphic graphic_picture graphicRef118214" href="/d/graphic/118214.html" rel="external">picture 1</a>) [<a href="#rid44">44</a>]. Microglia are inflammatory cells that respond to alterations in levels of cytokines; they are activated during various types of cerebral injury, including the secondary injury that occurs during reperfusion after ischemia [<a href="#rid45">45,46</a>]. These studies therefore suggest that various inflammatory pathways may participate in DKA-related cerebral injury.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Finally, studies in a rat DKA model have shown that DKA increases levels of inflammatory mediators in brain tissue lysates. The most marked elevations were noted among chemokines involved in recruitment and activation of microglia (CCL3 and CCL5). Interestingly, this study also found evidence of persistent neuroinflammation long after recovery from DKA, suggesting that DKA might trigger a chronic neuroinflammatory response that could contribute to neurodegeneration over time in patients with diabetes [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1">The precise roles of neuroinflammation and altered cerebral perfusion in causing DKA-related cerebral injury are the subject of ongoing investigation.</p><p></p><p class="headingAnchor" id="H3624478878"><span class="h1">CLINICAL PRESENTATION AND EVALUATION</span></p><p class="headingAnchor" id="H2300412314"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Studies documenting risk factors for clinically apparent cerebral injury in children with DKA are useful in identifying children requiring more intensive monitoring [<a href="#rid1">1-4</a>]. Important risk factors for cerebral injury are:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe acidosis at presentation of DKA [<a href="#rid1">1,3,20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased blood urea nitrogen at presentation (which may represent a greater degree of hypovolemia) [<a href="#rid1">1,2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lower initial partial pressure of carbon dioxide (pCO<sub>2</sub>) [<a href="#rid2">2,4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Young age (&lt;5 years) and new onset of diabetes – These are not independent risk factors, but they are markers for more severe DKA because they are associated with delayed diagnosis of DKA.</p><p></p><p>Use of bicarbonate therapy for correction of acidosis in DKA is also associated with increased risk of cerebral injury [<a href="#rid2">2,48</a>] and is no longer recommended for pediatric DKA treatment, except under specific rare circumstances. (See  <a class="medical medical_review" href="/d/html/5808.html" rel="external">"Diabetic ketoacidosis in children: Treatment and complications"</a>.)</p><p class="headingAnchor" id="H102756501"><span class="h2">Monitoring protocol</span></p><p class="bulletIndent1"><span class="glyph">●</span>Initial evaluation – All children presenting with DKA should have a rapid assessment of level of consciousness using the Glasgow Coma Scale  (<a class="graphic graphic_table graphicRef59662" href="/d/graphic/59662.html" rel="external">table 1B</a>) or a similar neurologic evaluation, with particular attention to findings associated with cerebral injury (see <a class="local">'Clinical criteria'</a> below). Assessment of risk factors for cerebral injury is also helpful in determining the level of monitoring that is necessary. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Care setting – Patients with risk factors for cerebral injury (see <a class="local">'Risk factors'</a> above), abnormalities in mental status, or other findings concerning for cerebral injury (see <a class="local">'Clinical criteria'</a> below) should be managed in a specialized unit in which careful clinical and biochemical monitoring can occur (most commonly in a pediatric intensive care unit) because abrupt deterioration in neurologic status can occur and should be treated immediately.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring – Neurologic monitoring using the Glasgow Coma Scale or other similar assessments should be repeated at least hourly during the first 12 to 24 hours of treatment  (<a class="graphic graphic_table graphicRef59662" href="/d/graphic/59662.html" rel="external">table 1B</a>). More frequent assessments may be necessary for children with altered mental status.</p><p></p><p class="headingAnchor" id="H118040128"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The presence of any of the symptoms listed below should raise suspicion for the possibility of cerebral injury [<a href="#rid26">26</a>]. Altered mental status in children with DKA can be caused by a variety of factors other than cerebral injury, including acidosis, other metabolic derangements, and sleep deprivation. Nonetheless, clinicians should maintain a high level of suspicion for evidence of cerebral injury and intervene promptly if the diagnosis is suspected.</p><p class="headingAnchor" id="H974012851"><span class="h2">Clinical criteria</span><span class="headingEndMark"> — </span>The following criteria have been proposed for clinical diagnosis of DKA-related cerebral injury  (<a class="graphic graphic_table graphicRef53017" href="/d/graphic/53017.html" rel="external">table 1A</a>) (modified from [<a href="#rid26">26</a>]):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minor criteria</strong> (moderately suspicious findings):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Headache – Although headache is frequently present at diagnosis of DKA, worsening or recurrence of headache during treatment is concerning</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vomiting – Vomiting is suspicious if it develops or recurs during treatment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Irritability, lethargy, or not easily aroused from sleep – These features are particularly suspicious if they occur or worsen after initiation of therapy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevated blood pressure – Eg, diastolic blood pressure &gt;90 mmHg</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major criteria</strong> (very suspicious findings):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal or deteriorating mental status after initiation of therapy, agitated behavior, or fluctuating level of consciousness</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inappropriate slowing of heart rate – Eg, decline more than 20 beats per minute that is not attributable to improved intravascular volume or sleep state</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Incontinence inappropriate for age</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic criteria</strong> (signs of significant brain injury, increased intracranial pressure, or brain herniation):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal motor or verbal response to pain</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decorticate or decerebrate posture</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal pupillary response or other cranial nerve (CN) palsy – Key steps are to evaluate extraocular movements (CN III, IV, and VI) and pupillary dilation and reactivity (CN II and III) (see  <a class="medical medical_review" href="/d/html/15360.html" rel="external">"Detailed neurologic assessment of infants and children", section on 'Cranial nerves'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal neurogenic respiratory pattern – Eg, grunting, abnormal tachypnea, Cheyne-Stokes respiration, apnea</p><p></p><p>In some cases, DKA-related cerebral injury may have other manifestations. Seizures have been described in some patients, while some other patients develop arginine vasopressin deficiency (previously called central diabetes insipidus), manifested as a rapidly rising serum sodium level.</p><p class="headingAnchor" id="H1442581974"><span class="h2">Provisional diagnosis and indications for treatment</span><span class="headingEndMark"> — </span>We suggest immediate treatment for patients with any of the following, using the criteria above [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>One diagnostic criterion</p><p class="bulletIndent1"><span class="glyph">●</span>Two major criteria</p><p class="bulletIndent1"><span class="glyph">●</span>One major and two minor criteria</p><p class="bulletIndent1"><span class="glyph">●</span>One major and one minor criterion (for children under five years of age)</p><p></p><p class="bulletIndent1">(See <a class="local">'Treatment'</a> below.)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment for cerebral injury should be initiated as soon as the disorder is diagnosed, based on the clinical criteria outlined above. It is appropriate to treat promptly based on clinical suspicion because untreated cerebral injury has a high rate of mortality and morbidity, and treatment with a hyperosmolar agent (<a class="drug drug_pediatric" data-topicid="12570" href="/d/drug information/12570.html" rel="external">mannitol</a> or hypertonic <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a>) may be beneficial. Evidence supporting the use of hyperosmolar treatments for cerebral injury consists of case reports and case series documenting rapid clinical improvement after administration of these agents in DKA-associated cerebral injury [<a href="#rid49">49-52</a>] and successful use in patients with cerebral edema due to other causes.</p><p>Although cerebral edema may be detectable on imaging studies in some children, edema is not uniformly present and may develop hours to days after neurologic decline [<a href="#rid26">26</a>]. For this reason, initial treatment decisions should not rely on findings from imaging studies [<a href="#rid53">53</a>]. Imaging studies should be considered after initiating treatment, depending on the clinical response, to detect cerebral herniation or impending herniation, cerebral infarction, hemorrhage, or thrombosis. All patients with suspected cerebral injury should be managed in an intensive care unit.</p><p>Treatment for cerebral injury consists of the following [<a href="#rid54">54</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Immediately give <a class="drug drug_pediatric" data-topicid="12570" href="/d/drug information/12570.html" rel="external">mannitol</a> 0.5 to 1 g/kg intravenously over 10 to 15 minutes. Mannitol administration can be repeated after 30 minutes. Effects of mannitol generally are rapidly apparent (within 15 minutes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjust fluid administration as indicated to maintain normal blood pressure and optimize cerebral perfusion. Avoid hypotension that might compromise cerebral perfusion pressure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administer oxygen as needed to maintain normal oxygen saturation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intubation may be necessary for patients with apnea or abnormal respirations or to protect the airway. Aggressive hyperventilation (ie, that brings the partial pressure of carbon dioxide [pCO<sub>2</sub>] below the level appropriate to the patient's level of acidosis) has been associated with poor outcomes of DKA-related cerebral injury and should be avoided unless absolutely necessary to treat elevated intracranial pressure [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring of intracranial pressure may be necessary in selected patients.</p><p></p><p>The mechanism of action of <a class="drug drug_pediatric" data-topicid="12570" href="/d/drug information/12570.html" rel="external">mannitol</a> in DKA-related cerebral injury is unclear. Improvements in mental status are often more rapidly evident than would be anticipated based on reductions in edema. These effects may result from improvements in blood viscosity and red blood cell deformability that have been described with mannitol treatment, with beneficial effects on cerebral blood flow [<a href="#rid55">55,56</a>].</p><p>Hypertonic (3%) <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> (2.5 to 5 mL/kg over 10 to 15 minutes) can be used if initial treatment with <a class="drug drug_pediatric" data-topicid="12570" href="/d/drug information/12570.html" rel="external">mannitol</a> does not result in improved mental status. For most patients, we suggest using hypertonic saline as a secondary intervention in patients with progressive symptoms and no response to mannitol. Some experts use hypertonic saline as a first-line treatment, especially for children who present with signs and symptoms of cerebral injury in the early phases of treatment, while they are still severely dehydrated and acidotic. One retrospective study found higher mortality rates in patients treated with hypertonic saline alone than in those treated with mannitol; however, these results may not reflect a causal association and should be interpreted with caution [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/106112.html" rel="external">"Elevated intracranial pressure (ICP) in children: Management", section on 'Hyperosmolar therapy'</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>The mortality rate among children with DKA who develop definite cerebral injury is approximately 20 to 25 percent. Among survivors, approximately 21 to 26 percent have permanent neurologic sequelae [<a href="#rid8">8,14,57</a>].</p><p>Risk factors for death or survival in a vegetative state were identified in a retrospective multicenter study of 61 children [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated blood urea nitrogen at the time of initial presentation</p><p class="bulletIndent1"><span class="glyph">●</span>Intubation with aggressive hyperventilation (targeting a partial pressure of carbon dioxide [pCO<sub>2</sub>] of less than 22 mmHg)</p><p class="bulletIndent1"><span class="glyph">●</span>Severe neurologic compromise at diagnosis of cerebral injury (all patients who either died or survived in a persistent vegetative state had Glasgow Coma Scale scores ≤7 when cerebral injury was diagnosed)</p><p></p><p>In addition to clinically apparent episodes of cerebral injury, multiple lines of evidence suggest that subtle cerebral injury occurs commonly during DKA. It is possible that clinically apparent cerebral injury may represent the most severe presentation of an otherwise common phenomenon. As an example, studies demonstrate subtle alterations in cognitive functioning, including deficits in memory, attention, and verbal intelligence quotient (IQ), in children with type 1 diabetes who have had one or more DKA episodes compared with children with diabetes but without a history DKA [<a href="#rid58">58-60</a>]. In a large study involving 1134 children with diabetes, a single episode of DKA was associated with subtle deficits in memory shortly after diagnosis of diabetes [<a href="#rid61">61</a>]. Repeated DKA episodes over time were associated with sizable declines in IQ. In addition, studies using magnetic resonance imaging (MRI) document cerebral microstructural alterations in children after recovery from DKA [<a href="#rid59">59,62</a>], while other studies have found elevated levels of neuron-specific enolase, a marker of neuronal injury, in children with uncomplicated DKA, as well as cerebral metabolic alterations suggestive of hypoxia/ischemia [<a href="#rid63">63-66</a>].</p><p class="headingAnchor" id="H2905632777"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111575.html" rel="external">"Society guideline links: Diabetes mellitus in children"</a> and  <a class="medical medical_society_guidelines" href="/d/html/113400.html" rel="external">"Society guideline links: Hyperglycemic emergencies"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence and outcomes</strong> – Cerebral injury (cerebral edema) occurs in 0.3 to 0.9 percent of cases of diabetic ketoacidosis (DKA) in children and is responsible for most DKA-related deaths. Among children with DKA who develop cerebral injury, the mortality rate is 20 to 25 percent and 21 to 26 percent of survivors have permanent neurologic sequelae. More subtle forms of cerebral injury occur commonly during DKA. A single episode of DKA may be associated with subtle deficits in memory, and multiple episodes of DKA are associated with cognitive declines. (See <a class="local">'Incidence'</a> above and <a class="local">'Outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Children who present with elevated blood urea nitrogen or more profound acidosis and hypocapnia are at greatest risk for cerebral injury. Younger children and those with new onset of diabetes are more likely to present with these risk factors because recognition of DKA is often delayed in these patients. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical monitoring</strong> – Children undergoing DKA treatment should be monitored for signs and symptoms of cerebral injury  (<a class="graphic graphic_table graphicRef53017 graphicRef59662" href="/d/graphic/53017.html" rel="external">table 1A-B</a>). (See <a class="local">'Monitoring protocol'</a> above and <a class="local">'Clinical criteria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decision to treat</strong> – Changes detectable on cerebral imaging studies may occur late in the development of cerebral injury. Therefore, the decision to treat should be based on clinical evaluation  (<a class="graphic graphic_table graphicRef53017" href="/d/graphic/53017.html" rel="external">table 1A</a>). Imaging may be useful to exclude other causes of neurologic deterioration but should not delay treatment. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>How to treat</strong> – Cerebral injury is associated with high mortality and morbidity and must be treated promptly with osmotic therapy when strongly suspected based on clinical criteria, even before imaging is obtained  (<a class="graphic graphic_table graphicRef53017" href="/d/graphic/53017.html" rel="external">table 1A</a>) (see <a class="local">'Treatment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest treatment with <a class="drug drug_pediatric" data-topicid="12570" href="/d/drug information/12570.html" rel="external">mannitol</a> (0.5 to 1 g/kg) rather than hypertonic <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Very limited evidence suggests that hypertonic saline may be associated with a higher mortality rate than mannitol.</p><p></p><p class="bulletIndent2">If there is no clinical improvement in mental status, the same dose should be repeated after 30 minutes. It is also reasonable to use hypertonic <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> (2.5 to 5 mL/kg over 10 to 15 minutes) if initial treatment with <a class="drug drug_pediatric" data-topicid="12570" href="/d/drug information/12570.html" rel="external">mannitol</a> does not result in improved mental status.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intubation and mechanical ventilation may be required; however, aggressive hyperventilation (ie, that brings the partial pressure of carbon dioxide [pCO<sub>2</sub>] below the level appropriate to the patient's level of acidosis) should be avoided.</p><p></p><p class="headingAnchor" id="H2178381644"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges George Jeha, MD, and Morey W Haymond, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lawrence SE, Cummings EA, Gaboury I, Daneman D. Population-based study of incidence and risk factors for cerebral edema in pediatric diabetic ketoacidosis. J Pediatr 2005; 146:688.</a></li><li><a class="nounderline abstract_t">Glaser N, Barnett P, McCaslin I, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med 2001; 344:264.</a></li><li><a class="nounderline abstract_t">Edge JA, Jakes RW, Roy Y, et al. The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children. Diabetologia 2006; 49:2002.</a></li><li><a class="nounderline abstract_t">Mahoney CP, Vlcek BW, DelAguila M. Risk factors for developing brain herniation during diabetic ketoacidosis. Pediatr Neurol 1999; 21:721.</a></li><li><a class="nounderline abstract_t">Edge JA, Ford-Adams ME, Dunger DB. Causes of death in children with insulin dependent diabetes 1990-96. Arch Dis Child 1999; 81:318.</a></li><li><a class="nounderline abstract_t">Krane EJ, Rockoff MA, Wallman JK, Wolfsdorf JI. Subclinical brain swelling in children during treatment of diabetic ketoacidosis. N Engl J Med 1985; 312:1147.</a></li><li><a class="nounderline abstract_t">Glasgow AM. Devastating cerebral edema in diabetic ketoacidosis before therapy. Diabetes Care 1991; 14:77.</a></li><li><a class="nounderline abstract_t">Marcin JP, Glaser N, Barnett P, et al. Factors associated with adverse outcomes in children with diabetic ketoacidosis-related cerebral edema. J Pediatr 2002; 141:793.</a></li><li><a class="nounderline abstract_t">Scibilia J, Finegold D, Dorman J, et al. Why do children with diabetes die? Acta Endocrinol Suppl (Copenh) 1986; 279:326.</a></li><li><a class="nounderline abstract_t">Levitsky L. Death from diabetes (DM) in hospitalized children (1970-1988). Pediatr Res 1991; 29:A195.</a></li><li><a class="nounderline abstract_t">Curtis JR, To T, Muirhead S, et al. Recent trends in hospitalization for diabetic ketoacidosis in ontario children. Diabetes Care 2002; 25:1591.</a></li><li><a class="nounderline abstract_t">Decourcey DD, Steil GM, Wypij D, Agus MS. Increasing use of hypertonic saline over mannitol in the treatment of symptomatic cerebral edema in pediatric diabetic ketoacidosis: an 11-year retrospective analysis of mortality*. Pediatr Crit Care Med 2013; 14:694.</a></li><li><a class="nounderline abstract_t">Hsia DS, Tarai SG, Alimi A, et al. Fluid management in pediatric patients with DKA and rates of suspected clinical cerebral edema. Pediatr Diabetes 2015; 16:338.</a></li><li><a class="nounderline abstract_t">Edge JA, Hawkins MM, Winter DL, Dunger DB. The risk and outcome of cerebral oedema developing during diabetic ketoacidosis. Arch Dis Child 2001; 85:16.</a></li><li><a class="nounderline abstract_t">Hoffman WH, Steinhart CM, el Gammal T, et al. Cranial CT in children and adolescents with diabetic ketoacidosis. AJNR Am J Neuroradiol 1988; 9:733.</a></li><li><a class="nounderline abstract_t">Glaser NS, Wootton-Gorges SL, Buonocore MH, et al. Frequency of sub-clinical cerebral edema in children with diabetic ketoacidosis. Pediatr Diabetes 2006; 7:75.</a></li><li><a class="nounderline abstract_t">Glaser NS, Marcin JP, Wootton-Gorges SL, et al. Correlation of clinical and biochemical findings with diabetic ketoacidosis-related cerebral edema in children using magnetic resonance diffusion-weighted imaging. J Pediatr 2008; 153:541.</a></li><li><a class="nounderline abstract_t">Harris GD, Fiordalisi I, Harris WL, et al. Minimizing the risk of brain herniation during treatment of diabetic ketoacidemia: a retrospective and prospective study. J Pediatr 1990; 117:22.</a></li><li><a class="nounderline abstract_t">Duck SC, Wyatt DT. Factors associated with brain herniation in the treatment of diabetic ketoacidosis. J Pediatr 1988; 113:10.</a></li><li><a class="nounderline abstract_t">Durr JA, Hoffman WH, Sklar AH, et al. Correlates of brain edema in uncontrolled IDDM. Diabetes 1992; 41:627.</a></li><li><a class="nounderline abstract_t">Silver SM, Clark EC, Schroeder BM, Sterns RH. Pathogenesis of cerebral edema after treatment of diabetic ketoacidosis. Kidney Int 1997; 51:1237.</a></li><li><a class="nounderline abstract_t">Kuppermann N, Ghetti S, Schunk JE, et al. Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis. N Engl J Med 2018; 378:2275.</a></li><li><a class="nounderline abstract_t">Glaser NS, Stoner MJ, Garro A, et al. Serum Sodium Concentration and Mental Status in Children With Diabetic Ketoacidosis. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Couch RM, Acott PD, Wong GW. Early onset fatal cerebral edema in diabetic ketoacidosis. Diabetes Care 1991; 14:78.</a></li><li><a class="nounderline abstract_t">Glaser NS, Quayle KS, McManemy JK, et al. Clinical Characteristics of Children with Cerebral Injury preceding Treatment of Diabetic Ketoacidosis. J Pediatr 2022; 250:100.</a></li><li><a class="nounderline abstract_t">Muir AB, Quisling RG, Yang MC, Rosenbloom AL. Cerebral edema in childhood diabetic ketoacidosis: natural history, radiographic findings, and early identification. Diabetes Care 2004; 27:1541.</a></li><li><a class="nounderline abstract_t">Glaser NS, Wootton-Gorges SL, Marcin JP, et al. Mechanism of cerebral edema in children with diabetic ketoacidosis. J Pediatr 2004; 145:164.</a></li><li><a class="nounderline abstract_t">Glaser NS, Tancredi DJ, Marcin JP, et al. Cerebral hyperemia measured with near infrared spectroscopy during treatment of diabetic ketoacidosis in children. J Pediatr 2013; 163:1111.</a></li><li><a class="nounderline abstract_t">Neumann-Haefelin T, Moseley ME, Albers GW. New magnetic resonance imaging methods for cerebrovascular disease: emerging clinical applications. Ann Neurol 2000; 47:559.</a></li><li><a class="nounderline abstract_t">Glaser N, Yuen N, Anderson SE, et al. Cerebral metabolic alterations in rats with diabetic ketoacidosis: effects of treatment with insulin and intravenous fluids and effects of bumetanide. Diabetes 2010; 59:702.</a></li><li><a class="nounderline abstract_t">Sener RN. Diffusion MRI: apparent diffusion coefficient (ADC) values in the normal brain and a classification of brain disorders based on ADC values. Comput Med Imaging Graph 2001; 25:299.</a></li><li><a class="nounderline abstract_t">Hoffman WH, Andjelkovic AV, Zhang W, et al. Insulin and IGF-1 receptors, nitrotyrosin and cerebral neuronal deficits in two young patients with diabetic ketoacidosis and fatal brain edema. Brain Res 2010; 1343:168.</a></li><li><a class="nounderline abstract_t">Hoffman WH, Artlett CM, Zhang W, et al. Receptor for advanced glycation end products and neuronal deficit in the fatal brain edema of diabetic ketoacidosis. Brain Res 2008; 1238:154.</a></li><li><a class="nounderline abstract_t">Hoffman WH, Stamatovic SM, Andjelkovic AV. Inflammatory mediators and blood brain barrier disruption in fatal brain edema of diabetic ketoacidosis. Brain Res 2009; 1254:138.</a></li><li><a class="nounderline abstract_t">Yuen N, Anderson SE, Glaser N, et al. Cerebral blood flow and cerebral edema in rats with diabetic ketoacidosis. Diabetes 2008; 57:2588.</a></li><li><a class="nounderline abstract_t">Hoffman WH, Pluta RM, Fisher AQ, et al. Transcranial Doppler ultrasound assessment of intracranial hemodynamics in children with diabetic ketoacidosis. J Clin Ultrasound 1995; 23:517.</a></li><li><a class="nounderline abstract_t">Ma L, Roberts JS, Pihoker C, et al. Transcranial Doppler-based assessment of cerebral autoregulation in critically ill children during diabetic ketoacidosis treatment. Pediatr Crit Care Med 2014; 15:742.</a></li><li><a class="nounderline abstract_t">Hoffman WH, Burek CL, Waller JL, et al. Cytokine response to diabetic ketoacidosis and its treatment. Clin Immunol 2003; 108:175.</a></li><li><a class="nounderline abstract_t">Hoffman WH, Passmore GG, Hannon DW, et al. Increased systemic Th17 cytokines are associated with diastolic dysfunction in children and adolescents with diabetic ketoacidosis. PLoS One 2013; 8:e71905.</a></li><li><a class="nounderline abstract_t">Omatsu T, Cepinskas G, Clarson C, et al. CXCL1/CXCL8 (GROα/IL-8) in human diabetic ketoacidosis plasma facilitates leukocyte recruitment to cerebrovascular endothelium in vitro. Am J Physiol Endocrinol Metab 2014; 306:E1077.</a></li><li><a class="nounderline abstract_t">Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004; 53:2079.</a></li><li><a class="nounderline abstract_t">Garro A, Chodobski A, Szmydynger-Chodobska J, et al. Circulating matrix metalloproteinases in children with diabetic ketoacidosis. Pediatr Diabetes 2017; 18:95.</a></li><li><a class="nounderline abstract_t">Woo M, Patterson EK, Cepinskas G, et al. Dynamic regulation of plasma matrix metalloproteinases in human diabetic ketoacidosis. Pediatr Res 2016; 79:295.</a></li><li><a class="nounderline abstract_t">Lo W, O'Donnell M, Tancredi D, et al. Diabetic ketoacidosis in juvenile rats is associated with reactive gliosis and activation of microglia in the hippocampus. Pediatr Diabetes 2016; 17:127.</a></li><li><a class="nounderline abstract_t">Chen YJ, Raman G, Bodendiek S, et al. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab 2011; 31:2363.</a></li><li><a class="nounderline abstract_t">Garden GA, Möller T. Microglia biology in health and disease. J Neuroimmune Pharmacol 2006; 1:127.</a></li><li><a class="nounderline abstract_t">Glaser N, Chu S, Hung B, et al. Acute and chronic neuroinflammation is triggered by diabetic ketoacidosis in a rat model. BMJ Open Diabetes Res Care 2020; 8.</a></li><li><a class="nounderline abstract_t">Bureau MA, Bégin R, Berthiaume Y, et al. Cerebral hypoxia from bicarbonate infusion in diabetic acidosis. J Pediatr 1980; 96:968.</a></li><li><a class="nounderline abstract_t">Franklin B, Liu J, Ginsberg-Fellner F. Cerebral edema and ophthalmoplegia reversed by mannitol in a new case of insulin-dependent diabetes mellitus. Pediatrics 1982; 69:87.</a></li><li><a class="nounderline abstract_t">Shabbir N, Oberfield SE, Corrales R, et al. Recovery from symptomatic brain swelling in diabetic ketoacidosis. Clin Pediatr (Phila) 1992; 31:570.</a></li><li><a class="nounderline abstract_t">Roberts MD, Slover RH, Chase HP. Diabetic ketoacidosis with intracerebral complications. Pediatr Diabetes 2001; 2:109.</a></li><li><a class="nounderline abstract_t">Curtis JR, Bohn D, Daneman D. Use of hypertonic saline in the treatment of cerebral edema in diabetic ketoacidosis (DKA). Pediatr Diabetes 2001; 2:191.</a></li><li><a class="nounderline abstract_t">Soto-Rivera CL, Asaro LA, Agus MS, DeCourcey DD. Suspected Cerebral Edema in Diabetic Ketoacidosis: Is There Still a Role for Head CT in Treatment Decisions? Pediatr Crit Care Med 2017; 18:207.</a></li><li><a class="nounderline abstract_t">Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes 2018; 19 Suppl 27:155.</a></li><li><a class="nounderline abstract_t">Rosner MJ, Coley I. Cerebral perfusion pressure: a hemodynamic mechanism of mannitol and the postmannitol hemogram. Neurosurgery 1987; 21:147.</a></li><li><a class="nounderline abstract_t">Soriano SG, McManus ML, Sullivan LJ, et al. Cerebral blood flow velocity after mannitol infusion in children. Can J Anaesth 1996; 43:461.</a></li><li><a class="nounderline abstract_t">Wolfsdorf J, Glaser N, Sperling MA, American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. Diabetes Care 2006; 29:1150.</a></li><li><a class="nounderline abstract_t">Ghetti S, Lee JK, Sims CE, et al. Diabetic ketoacidosis and memory dysfunction in children with type 1 diabetes. J Pediatr 2010; 156:109.</a></li><li><a class="nounderline abstract_t">Cameron FJ, Scratch SE, Nadebaum C, et al. Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. Diabetes Care 2014; 37:1554.</a></li><li><a class="nounderline abstract_t">Cato MA, Mauras N, Mazaika P, et al. Longitudinal Evaluation of Cognitive Functioning in Young Children with Type 1 Diabetes over 18 Months. J Int Neuropsychol Soc 2016; 22:293.</a></li><li><a class="nounderline abstract_t">Ghetti S, Kuppermann N, Rewers A, et al. Cognitive Function Following Diabetic Ketoacidosis in Children With New-Onset or Previously Diagnosed Type 1 Diabetes. Diabetes Care 2020; 43:2768.</a></li><li><a class="nounderline abstract_t">Antenor-Dorsey JA, Meyer E, Rutlin J, et al. White matter microstructural integrity in youth with type 1 diabetes. Diabetes 2013; 62:581.</a></li><li><a class="nounderline abstract_t">Wootton-Gorges SL, Buonocore MH, Kuppermann N, et al. Cerebral proton magnetic resonance spectroscopy in children with diabetic ketoacidosis. AJNR Am J Neuroradiol 2007; 28:895.</a></li><li><a class="nounderline abstract_t">Wootton-Gorges SL, Buonocore MH, Kuppermann N, et al. Detection of cerebral {beta}-hydroxy butyrate, acetoacetate, and lactate on proton MR spectroscopy in children with diabetic ketoacidosis. AJNR Am J Neuroradiol 2005; 26:1286.</a></li><li><a class="nounderline abstract_t">Hamed S, Metwalley KA, Farghaly HS, Sherief T. Serum Levels of Neuron-Specific Enolase in Children With Diabetic Ketoacidosis. J Child Neurol 2017; 32:475.</a></li><li><a class="nounderline abstract_t">Wootton-Gorges SL, Buonocore MH, Caltagirone RA, et al. Progressive decrease in N-acetylaspartate/Creatine ratio in a teenager with type 1 diabetes and repeated episodes of ketoacidosis without clinically apparent cerebral edema: Evidence for permanent brain injury. AJNR Am J Neuroradiol 2010; 31:780.</a></li></ol></div><div id="topicVersionRevision">Topic 5829 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870676" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Population-based study of incidence and risk factors for cerebral edema in pediatric diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172153" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16847700" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10580884" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Risk factors for developing brain herniation during diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10490436" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Causes of death in children with insulin dependent diabetes 1990-96.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3920521" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Subclinical brain swelling in children during treatment of diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1899369" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Devastating cerebral edema in diabetic ketoacidosis before therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12461495" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Factors associated with adverse outcomes in children with diabetic ketoacidosis-related cerebral edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3096039" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Why do children with diabetes die?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Death from diabetes (DM) in hospitalized children (1970-1988)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196432" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Recent trends in hospitalization for diabetic ketoacidosis in ontario children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23863818" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Increasing use of hypertonic saline over mannitol in the treatment of symptomatic cerebral edema in pediatric diabetic ketoacidosis: an 11-year retrospective analysis of mortality*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25800410" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Fluid management in pediatric patients with DKA and rates of suspected clinical cerebral edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11420189" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The risk and outcome of cerebral oedema developing during diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3135717" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cranial CT in children and adolescents with diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16629712" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Frequency of sub-clinical cerebral edema in children with diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18589447" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Correlation of clinical and biochemical findings with diabetic ketoacidosis-related cerebral edema in children using magnetic resonance diffusion-weighted imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2115081" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Minimizing the risk of brain herniation during treatment of diabetic ketoacidemia: a retrospective and prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3133455" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Factors associated with brain herniation in the treatment of diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1568533" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Correlates of brain edema in uncontrolled IDDM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9083292" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pathogenesis of cerebral edema after treatment of diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29897851" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34373322" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Serum Sodium Concentration and Mental Status in Children With Diabetic Ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1899370" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Early onset fatal cerebral edema in diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35944716" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical Characteristics of Children with Cerebral Injury preceding Treatment of Diabetic Ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220225" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cerebral edema in childhood diabetic ketoacidosis: natural history, radiographic findings, and early identification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15289761" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mechanism of cerebral edema in children with diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23871731" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cerebral hyperemia measured with near infrared spectroscopy during treatment of diabetic ketoacidosis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10805325" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : New magnetic resonance imaging methods for cerebrovascular disease: emerging clinical applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20028943" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cerebral metabolic alterations in rats with diabetic ketoacidosis: effects of treatment with insulin and intravenous fluids and effects of bumetanide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11356324" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Diffusion MRI: apparent diffusion coefficient (ADC) values in the normal brain and a classification of brain disorders based on ADC values.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20420811" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Insulin and IGF-1 receptors, nitrotyrosin and cerebral neuronal deficits in two young patients with diabetic ketoacidosis and fatal brain edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18775683" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Receptor for advanced glycation end products and neuronal deficit in the fatal brain edema of diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19103180" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Inflammatory mediators and blood brain barrier disruption in fatal brain edema of diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18633109" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cerebral blood flow and cerebral edema in rats with diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8537473" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Transcranial Doppler ultrasound assessment of intracranial hemodynamics in children with diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25072475" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Transcranial Doppler-based assessment of cerebral autoregulation in critically ill children during diabetic ketoacidosis treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14499240" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cytokine response to diabetic ketoacidosis and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24013901" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Increased systemic Th17 cytokines are associated with diastolic dysfunction in children and adolescents with diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24619879" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : CXCL1/CXCL8 (GROα/IL-8) in human diabetic ketoacidosis plasma facilitates leukocyte recruitment to cerebrovascular endothelium in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277389" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26843101" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Circulating matrix metalloproteinases in children with diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26492282" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Dynamic regulation of plasma matrix metalloproteinases in human diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25594864" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diabetic ketoacidosis in juvenile rats is associated with reactive gliosis and activation of microglia in the hippocampus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21750563" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18040779" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Microglia biology in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33318070" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acute and chronic neuroinflammation is triggered by diabetic ketoacidosis in a rat model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6768868" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cerebral hypoxia from bicarbonate infusion in diabetic acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6798545" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cerebral edema and ophthalmoplegia reversed by mannitol in a new case of insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1334813" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Recovery from symptomatic brain swelling in diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15016193" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Diabetic ketoacidosis with intracerebral complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15016186" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Use of hypertonic saline in the treatment of cerebral edema in diabetic ketoacidosis (DKA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28107262" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Suspected Cerebral Edema in Diabetic Ketoacidosis: Is There Still a Role for Head CT in Treatment Decisions?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29900641" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3116451" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cerebral perfusion pressure: a hemodynamic mechanism of mannitol and the postmannitol hemogram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8723852" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cerebral blood flow velocity after mannitol infusion in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16644656" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19833353" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Diabetic ketoacidosis and memory dysfunction in children with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24855156" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26786245" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Longitudinal Evaluation of Cognitive Functioning in Young Children with Type 1 Diabetes over 18 Months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32962981" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cognitive Function Following Diabetic Ketoacidosis in Children With New-Onset or Previously Diagnosed Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23139349" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : White matter microstructural integrity in youth with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17494665" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cerebral proton magnetic resonance spectroscopy in children with diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15891198" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Detection of cerebral {beta}-hydroxy butyrate, acetoacetate, and lactate on proton MR spectroscopy in children with diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28056586" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Serum Levels of Neuron-Specific Enolase in Children With Diabetic Ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19926705" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Progressive decrease in N-acetylaspartate/Creatine ratio in a teenager with type 1 diabetes and repeated episodes of ketoacidosis without clinically apparent cerebral edema: Evidence for permanent brain injury.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
